1-[2-(6-Acetyl-2,3,4-trihydroxyphenyl)-3,4,5-trihydroxyphenyl]ethanone

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 英文名称: 1-[2-(6-Acetyl-2,3,4-trihydroxyphenyl)-3,4,5-trihydroxyphenyl]ethanone
• 化学式: C₁₆H₁₄O₈
• 分子量: 334.28
• InChiKey: MXXDMVPRIRUXCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  156
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof
  申请人：Amazentis SA

  公开号：US20140018415A1

  公开（公告）日：2014-01-16

  Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

  本发明涉及用于增加自噬和促进寿命的方法、化合物和组合物。所述方法、化合物和组合物涉及urolithins和urolithin前体及其使用。某些urolithins由公式I表示，而某些urolithin前体由公式IV表示。所述urolithin可以是urolithin A、urolithin B、urolithin C或urolithin D。所述urolithin前体可以是鞣花酸或鞣花酸单宁。所述方法包括化合物和组合物的体内、体外和体外使用。
• COMPOUNDS, COMPOSITIONS AND METHODS FOR PROTECTING BRAIN HEALTH IN NEURODEGENERATIVE DISORDERS
  申请人：Amazetis SA

  公开号：EP3202399A1

  公开（公告）日：2017-08-09

  Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.

  本发明的各个方面涉及治疗神经退行性疾病和/或改善大脑健康的化合物、提取物及其组合物以及使用方法。在某些实施方案中，所述化合物是石榴类黄酮。
• Lipase Inhibitors
  申请人：Fukui Yuko

  公开号：US20070254948A1

  公开（公告）日：2007-11-01

  The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents. The present invention provides lipase inhibitory agents comprising at least one of compounds represented by formula I below: wherein R 1 , R 2 and R 3 independently represent H or a gallic acid residue, and R 4 and R 5 represent H or a gallic acid residue, or R 4 and R 5 together form an HHDP group represented by the formula below: provided that at least two of R 1 to R 5 represent a gallic acid residue or when all of R 1 , R 2 and R 3 are H, R 4 and R 5 together form the HHDP group; as well as foods and beverages and medicines containing said lipase inhibitory agents.
• Medical devices and methods for local delivery of elastin-stabilizing compounds
  申请人：Biggs Paul David

  公开号：US20070282422A1

  公开（公告）日：2007-12-06

  This invention relates to medical devices and an elastin-stabilizing compound, such as a phenolic tannin, the medical device being adapted to release the elastin-stabilizing compound within a body of a patient. This invention also relates to medical devices and methods of treatment of disease, such as aneurysms and aortic dissection. Medical devices may include coated stents, grafts, stent grafts, balloons and catheters.
• Lipase inhibitors
  申请人：Fukui Yuko

  公开号：US20090042812A1

  公开（公告）日：2009-02-12

  The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents. The present invention provides lipase inhibitory agents comprising at least one of compounds represented by formula I below: wherein R 1 , R 2 and R 3 independently represent H or a gallic acid residue, and R 4 and R 5 represent H or a gallic acid residue, or R 4 and R 5 together form an HHDP group represented by the formula below: provided that at least two of R 1 to R 5 represent a gallic acid residue or when all of R 1 , R 2 and R 3 are H, R 4 and R 5 together form the HHDP group; as well as foods and beverages and medicines containing said lipase inhibitory agents.